Emergent Biosolutions Inc (NYSE:EBS) Director Kathryn C. Zoon sold 4,242 shares of the company’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $69.74, for a total value of $295,837.08. Following the completion of the sale, the director now directly owns 33,972 shares of the company’s stock, valued at $2,369,207.28. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Emergent Biosolutions stock opened at $67.54 on Friday. Emergent Biosolutions Inc has a twelve month low of $36.38 and a twelve month high of $71.01. The company has a quick ratio of 4.29, a current ratio of 5.52 and a debt-to-equity ratio of 0.01. The company has a market cap of $3.54 billion, a price-to-earnings ratio of 35.55, a P/E/G ratio of 1.58 and a beta of 1.27.
Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.07). Emergent Biosolutions had a return on equity of 12.89% and a net margin of 14.19%. The company had revenue of $173.70 million for the quarter, compared to analyst estimates of $185.16 million. During the same period in the previous year, the business posted $0.73 earnings per share. The firm’s revenue was up 16.3% compared to the same quarter last year. As a group, research analysts forecast that Emergent Biosolutions Inc will post 2.2 EPS for the current year.
EBS has been the subject of a number of research analyst reports. Goldman Sachs Group raised Emergent Biosolutions from a “neutral” rating to a “buy” rating and upped their target price for the company from $60.00 to $75.00 in a research report on Friday, November 2nd. Wells Fargo & Co set a $61.00 price objective on Emergent Biosolutions and gave the stock a “hold” rating in a research report on Friday, August 10th. Cantor Fitzgerald increased their price objective on Emergent Biosolutions from $68.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, November 2nd. Zacks Investment Research cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Monday, August 20th. Finally, Cowen reaffirmed a “hold” rating and set a $49.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, August 29th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $66.25.
A number of institutional investors have recently bought and sold shares of EBS. BlackRock Inc. raised its stake in shares of Emergent Biosolutions by 18.2% during the 3rd quarter. BlackRock Inc. now owns 6,350,905 shares of the biopharmaceutical company’s stock worth $418,078,000 after buying an additional 978,194 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Emergent Biosolutions by 10.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,066,511 shares of the biopharmaceutical company’s stock worth $104,338,000 after buying an additional 198,600 shares in the last quarter. FMR LLC raised its stake in shares of Emergent Biosolutions by 192.7% during the 2nd quarter. FMR LLC now owns 290,507 shares of the biopharmaceutical company’s stock worth $14,668,000 after buying an additional 191,248 shares in the last quarter. Rice Hall James & Associates LLC raised its stake in shares of Emergent Biosolutions by 18.1% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,141,021 shares of the biopharmaceutical company’s stock worth $57,610,000 after buying an additional 174,614 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Emergent Biosolutions by 86.1% during the 3rd quarter. Prudential Financial Inc. now owns 336,554 shares of the biopharmaceutical company’s stock worth $22,156,000 after buying an additional 155,666 shares in the last quarter. 82.76% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Kathryn C. Zoon Sells 4,242 Shares of Emergent Biosolutions Inc (EBS) Stock” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/11/10/kathryn-c-zoon-sells-4242-shares-of-emergent-biosolutions-inc-ebs-stock.html.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Further Reading: Do You Need a Fiduciary?
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.